<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefotaxime (United States: Limited availability): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefotaxime (United States: Limited availability): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefotaxime (United States: Limited availability): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9221" href="/d/html/9221.html" rel="external">see "Cefotaxime (United States: Limited availability): Drug information"</a> and <a class="drug drug_patient" data-topicid="11317" href="/d/html/11317.html" rel="external">see "Cefotaxime (United States: Limited availability): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1045979"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462397"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gestational age-directed dosing </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27572399','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27572399','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IV, IM:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Gestational Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Postnatal</b>
<b>Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&lt;32 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">&lt;7 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≥32 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IV, IM:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Body</p>
<p style="text-indent:0em;">Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Postnatal</p>
<p style="text-indent:0em;">Age</p></th>
<th align="center">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="3" valign="middle">
<p style="text-indent:0em;">≤2 kg</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center" rowspan="3" valign="middle">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">37.5 mg/kg/dose every 6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 6 hours</p></td></tr></tbody></table>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53573596-e9e3-4945-8eee-4664ba4ea8f5">Gonococcal infections, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infections, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scalp abscess or</i>
<i>disseminated gonococcal infection (including sepsis and arthritis)</i>: Neonates: IV, IM: 25 mg/kg/dose every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note:</b> Dosing is significantly lower than other contemporary dosages; use clinical judgment to determine if appropriate for patient scenario. See “Meningitis” section for gonococcal meningitis recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ophthalmia neonatorum: </i>
<b>Note:</b> Only recommended for patients who cannot receive ceftriaxone (eg, due to simultaneous IV calcium administration).</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: IV, IM: 100 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-3415944','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-3415944','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea65a8b1-e322-4417-b372-ae2b2b3d970d">Meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis: Note:</b> Duration of therapy is dependent on pathogen and clinical response; for gram-negative meningitis, typically treat for ≥21 days and ≥14 days after the first negative cerebrospinal fluid culture; for gonococcal meningitis, treat for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29437625','lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29437625','lexi-content-ref-15494903'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤7 days: IV: 100 to 150 mg/kg/<b>day </b>divided every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;7 days: IV: 150 to 200 mg/kg/<b>day</b> divided every 6 to 8 hours.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F147520"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional intermittent infusion method: </i>Infants, Children, and Adolescents: IV, IM: 150 to 180 mg/kg/day in divided doses every 4 to 8 hours; maximum dose: 2,000 mg/dose; higher daily doses are recommended for some indications (eg, meningitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.2'])">Ref</a></span>). <b>Note:</b> Based on pharmacokinetic modeling, dosing intervals of at least every 6 hours may be required to reach pharmacodynamic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28980166','lexi-content-ref-35383374','lexi-content-ref-29378711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28980166','lexi-content-ref-35383374','lexi-content-ref-29378711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion dosing:</i> Limited data available: Infants, Children, and Adolescents: IV: 100 to 200 mg/kg/<b>day</b> infused continuously over 24 hours; maximum daily dose: 12 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28980166','lexi-content-ref-18791659','lexi-content-ref-31432468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28980166','lexi-content-ref-18791659','lexi-content-ref-31432468'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7dd1e40e-580e-41e4-873e-e884b1e9396a">Acute bacterial rhinosinusitis, severe infection requiring hospitalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 100 to 200 mg/kg/<b>day</b> in divided doses every 6 hours for 10 to 14 days; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment</b>: Children and Adolescents: IV: 200 mg/kg/<b>day</b> in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for ≥4 weeks depending on pathogen and valve type; longer durations may be necessary; use in combination with other antibiotics depending on pathogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0938324d-f9b1-4c15-b82a-388a56f129fe">Gonococcal infection, disseminated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, disseminated (arthritis and arthritis-dermatitis syndrome) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV: 1,000 mg every 8 hours. Total duration of therapy is at least 7 days (including oral step-down therapy); can usually switch to susceptibility-guided oral therapy after 24 to 48 hours. Give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> in divided doses every 6 to 8 hours in combination with metronidazole; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>). Typical duration of therapy is 4 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection) (alternative agent):</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum daily dose: 6,000 <b>mg/day. </b>Duration of therapy depends on clinical syndrome; treat meningitis or radiculopathy for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea65a8b1-e322-4417-b372-ae2b2b3d970d">Meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis:</b> Infants, Children, and Adolescents: IV: 225 to 300 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum dose: 2,000 mg/dose; use in combination with vancomycin for empiric coverage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>); some experts recommend 300 mg/kg/day divided every 4 to 6 hours with a maximum daily dose of 12 <b>g</b>/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>)<b>:</b> Infants, Children, and Adolescents: Intraperitoneal:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent: 30 mg/kg/dose every 24 hours in the long dwell.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 250 mg per liter; <b>Note:</b> 125 mg/liter has also been recommended as a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (CAP): </b>Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-21880587','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-21880587','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Use as part of an appropriate combination regimen if methicillin-resistant <i>Staphylococcus aureus</i> or atypical pathogens are of concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0d17789-80cc-4fb4-9936-76ee229a4591">Salmonellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Salmonellosis: </b>Adolescents with HIV: IV: 1,000 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="29d4e108-46ce-4be8-bd73-a5bb3e8f3de1">Skin and soft tissue infection, necrotizing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, necrotizing</b>: Infants, Children, and Adolescents: IV: 200 mg/kg/<b>day</b> in divided doses every 6 hours in combination with metronidazole or clindamycin; maximum dose: 2,000 mg/dose. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 mg/kg within 60 minutes prior to surgical incision; may repeat in 3 hours if procedure is lengthy or if there is excessive blood loss; maximum dose: 1,000 mg; a larger maximum dose (2,000 mg) is recommended for patients weighing ≥120 kg or with BMI &gt;30 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Infants, Children, and Adolescents: IM, IV: 150 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum dose: 2,000 mg/dose. Treatment duration dependent on age of patient, response to therapy, and extent of involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-29292282','lexi-content-ref-manu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-29292282','lexi-content-ref-manu.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083996"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 100 to 200 mg/kg/<b>day</b> divided every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: 35 to 70 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): 35 to 70 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CRRT: 35 to 70 mg/kg/dose every 12 hours.</p></div>
<div class="block dohp drugH1Div" id="F51083997"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F147497"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9221" href="/d/html/9221.html" rel="external">see "Cefotaxime (United States: Limited availability): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7dd1e40e-580e-41e4-873e-e884b1e9396a">Acute bacterial rhinosinusitis, severe infection requiring hospitalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization (off-label use):</b>
<b>IV:</b> 2 g every 4 to 6 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a431e4d5-7cdc-40e4-ab99-a34db186cec0">Bite wound</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound (animal) (off-label use):</b>
<b>IV:</b> 1 to 2 g every 6 to 8 hours in combination with clindamycin or metronidazole for anaerobic coverage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="416ea998-15ea-46d3-8f32-34fe3d0fbb64">Brain abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain abscess (empiric treatment):</b>
<b>IV:</b> 2 g every 4 to 6 hours in combination with other antimicrobial therapy as warranted (eg, metronidazole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20846891','lexi-content-ref-25075836','lexi-content-ref-16239034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20846891','lexi-content-ref-25075836','lexi-content-ref-16239034'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b37fd58-aca4-495f-8e85-ead486fa5f82">Cesarean delivery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cesarean delivery:</b>
<b>IM, IV:</b> 1 g IV as soon as the umbilical cord is clamped, then 1 g IV or IM at 6 and 12 hours after the first dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (hospitalized patients without risk factors for <i>P. aeruginosa</i>) (off-label use): IV:</b> 1 g every 8 hours for 5 to 7 days; may switch to oral therapy following clinical improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Sethi.2021','lexi-content-ref-16869814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Sethi.2021','lexi-content-ref-16869814'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0938324d-f9b1-4c15-b82a-388a56f129fe">Gonococcal infection, disseminated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, disseminated (arthritis and arthritis-dermatitis syndrome) (alternative agent) (off-label use):</b>
<b>IV:</b> 1 g every 8 hours. Total duration of therapy is at least 7 days (including oral step-down therapy); can usually switch to susceptibility-guided oral therapy after 24 to 48 hours. Give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="211497db-429c-4f08-a5f9-b2bc63113006">Gonococcal infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, uncomplicated (infection of the cervix, rectum, or urethra) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use cefotaxime only if ceftriaxone is unavailable given a lack of contemporary efficacy data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 500 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-8235924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-8235924'])">Ref</a></span>); give in combination with treatment for chlamydia if it has not been excluded. <b>Note:</b> When treatment failure is suspected (eg, detection of <i>N. gonorrhoeae</i> after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ee5e31-a0d3-4b7c-8c46-718f1da32611">Intra-abdominal infection, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate (community-acquired infection in patients without risk factors for resistance or treatment failure):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV: </b>2 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2021'])">Ref</a></span>). <b>Note: </b>The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, perforated appendix, diverticulitis, intra-abdominal abscess): </i>
<b>IV:</b> 2 g every 8 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2019'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2019','lexi-content-ref-Pemberton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2019','lexi-content-ref-Pemberton.2019'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carditis, </i>
<i>patients requiring hospitalization:</i>
<b>IV:</b> 2 g every 8 hours for 14 to 21 days (including oral step-down therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute neurologic disease (eg, meningitis, radiculopathy), patients requiring hospitalization:</i>
<b>IV:</b> 2 g every 8 hours for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Late neurologic disease:</i>
<b>IV:</b> 2 g every 8 hours for 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent arthritis after adequate oral treatment:</i>
<b>IV:</b> 2 g every 8 hours for 14 days; may extend to 28 days if inflammation is not resolving (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b> As a component of empiric therapy (community-acquired infections) or pathogen-specific therapy (eg, <i>Cutibacterium acnes</i>, <i>H. influenzae</i>, <i>N. meningitidis</i>, <i>S. agalactiae</i>, <i>S. pneumoniae</i>, and susceptible gram-negative bacilli; alternative agent for certain pathogens):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 4 to 6 hours; for empiric therapy, use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Inpatients without risk factors for <i>Pseudomonas aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g every 8 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8a572e1-fbbc-4c4a-9074-2127a806c755">
<i>Salmonella</i> species infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Salmonella</i> species infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Enteric fever (Salmonella typhi and paratyphi):</i> Empiric therapy for severe disease or an alternative directed therapy for quinolone-nonsusceptible infection: <b>IV:</b> 1 to 2 g every 6 to 8 hours for 10 to 14 days. <b>Note:</b> May be switched to an oral regimen based on susceptibility testing, if available. Geographic location at time of acquisition impacts risk of resistance; cefotaxime is not recommended if there is concern for extensively drug-resistant <i>Salmonella</i> spp. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ryan.2020','lexi-content-ref-WHO.2003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ryan.2020','lexi-content-ref-WHO.2003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal Salmonella GI infection:</i>
<b>IV:</b> 1 to 2 g every 8 hours for 3 to 14 days (7 to 14 days in HIV-infected patients with a CD4 count ≥200 cells/mm<sup>3</sup>). Immunosuppressed patients (eg, HIV infected with CD4 count &lt;200 cells/mm<sup>3</sup>) warrant a longer duration of treatment (eg, weeks to months). <b>Note:</b> Reserve antibiotic treatment for patients with severe illness or at high risk of invasive disease (eg, extremes of age, immunosuppression); reserve parenteral therapy for those who cannot tolerate oral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHSS.2020','lexi-content-ref-Hohmann.2020a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHSS.2020','lexi-content-ref-Hohmann.2020a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal Salmonella bloodstream infection:</i>
<b>IV:</b> 1 to 2 g every 8 hours for 14 days. <b>Note:</b> Immunosuppressed patients (eg, HIV infected with CD4 count &lt;200 cells/mm<sup>3</sup>) and those with an extraintestinal focus of infection warrant a longer duration of treatment (eg, weeks to months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHSS.2020','lexi-content-ref-Hohmann.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHSS.2020','lexi-content-ref-Hohmann.2020b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e85137ee-a6e6-4f50-a709-1ddd1ba6651e">Sepsis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis:</b>
<b>IV:</b> 2 g every 6 to 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9357c8a8-bc61-4588-803a-17d7cba42c78">Septic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (as a component of empiric therapy for traumatic bacterial arthritis without risk factors for <i>P. aeruginosa</i>; pathogen-directed therapy for gram-negative bacilli): IV:</b> 2 g every 8 hours. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy. For empiric therapy, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="29d4e108-46ce-4be8-bd73-a5bb3e8f3de1">Skin and soft tissue infection, necrotizing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, necrotizing (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Polymicrobial infection:</i>
<b>IV:</b> 2 g every 6 hours, in combination with metronidazole or clindamycin for empiric therapy of polymicrobial infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Necrotizing infection due to Vibrio vulnificus:</i>
<b>IV:</b> 2 g every 8 hours, in combination with doxycycline. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5753b930-8bad-462f-9c65-900e92275bf5">Spontaneous bacterial peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients without sepsis or risk for multidrug resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours; duration is for 5 to 7 days, as long as fever and pain have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.1','lexi-content-ref-Runyon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.1','lexi-content-ref-Runyon.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (off-label use):</b>
<b>IV:</b> 1 g within 60 minutes prior to surgical incision. Doses may be repeated in 3 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Obesity:</i> The ASHP/IDSA/SIS/SHEA guidelines recommend that for patients weighing ≥120 kg (or alternatively defined as BMI &gt;30 kg/m<sup>2</sup>), a dose of 2 g within 60 minutes prior to surgical incision should be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991212"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Cefotaxime Dose Adjustments for Altered Kidney Function</b>
<sup>a</sup></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual indication-specific dose is 1 to 2 g every 8 hours<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual indication-specific dose is 1 to 2 g every 6 hours<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual indication-specific dose is 2 g every 4 hours<sup>b</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Expert opinion derived from Bouchet 1991; Matzke 1985; Seguin 2009.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Expert opinion only.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Dialyzable (~40%) (Ings 1982): When scheduled dose falls on a dialysis day, administer after hemodialysis.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;10 to 50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 6 to 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≤10 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 12 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Dose as for CrCl &gt;10 to 50 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">PIRRT days: Dose as for CrCl &gt;10 to 50 mL/minute (on PIRRT days, when feasible administer one of the scheduled doses after the PIRRT session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: Dose as for CrCl ≤10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988417"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F147463"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤2%), skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (≤1%), diarrhea (≤1%), nausea (≤1%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site (IM ≤4%), inflammation at injection site (IV ≤4%), pain at injection site (IM ≤4%), tenderness at injection site (IM ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Acute generalized exanthematous pustulosis, acute renal failure, agranulocytosis, anaphylaxis, bone marrow failure, brain disease, candidiasis, cardiac arrhythmia (after rapid IV injection via central catheter), cholestasis, <i>Clostridioides difficile</i>-associated diarrhea, dizziness, erythema multiforme, granulocytopenia, headache, hemolytic anemia, hepatitis, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, injection site phlebitis, interstitial nephritis, jaundice, leukopenia, local irritation, neutropenia, pancytopenia, positive direct Coombs test, pseudomembranous colitis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis</p></div>
<div class="block coi drugH1Div" id="F147479"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefotaxime, any component of the formulation, or other cephalosporins</p></div>
<div class="block war drugH1Div" id="F147460"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmia: A potentially life-threatening arrhythmia has been reported in patients who received a rapid (&lt;1 minute) bolus injection via central venous catheter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Granulocytopenia: Granulocytopenia and more rarely agranulocytosis may develop during prolonged treatment (&gt;10 days).</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tissue inflammation: Minimize tissue inflammation by changing infusion sites when needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colitis: Use with caution in patients with a history of colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.</p></div>
<div class="block foc drugH1Div" id="F147472"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F147456"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323047"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefotaxime Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $11.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $23.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866242"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612381"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus. Doses of 2,000 mg should be divided and administered at two different sites.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: May be administered over 3 to 5 minutes; avoid rapid injection (&lt;1 minute) due to association with arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion: Infuse over 15 to 30 minutes.</p></div>
<div class="block adm drugH1Div" id="F147476"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject deep IM into large muscle mass. Individual doses of 2 g may be given if the dose is divided and administered in different IM sites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Can be administered IV bolus over at least 3 to 5 minutes or as an IV intermittent infusion over 15 to 30 minutes.</p></div>
<div class="block sts drugH1Div" id="F24956504"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials below 30°C (86°F).  Protect from light. Reconstituted solution is stable for 12 to 24 hours at room temperature, 7 to 10 days when refrigerated, for 13 weeks when frozen. For IV infusion in NS or D<sub>5</sub>W, solution is stable for 24 hours at room temperature, 5 days when refrigerated, or 13 weeks when frozen in Viaflex plastic containers. Thawed solutions of frozen premixed bags are stable for 24 hours at room temperature or 10 days when refrigerated.</p></div>
<div class="block usep drugH1Div" id="F53565925"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of susceptible lower respiratory tract, skin and soft tissue, bone and joint, intra-abdominal, GU tract, CNS, bacteremic, and gynecologic infections (FDA approved in all ages); prevention of postoperative surgical-site infection in contaminated or potentially contaminated surgical procedures (eg, GI and GU tract surgeries and hysterectomy [abdominal or vaginal]) and caesarian section (FDA approved in all ages); has also been used for the treatment of endocarditis, Lyme disease, and peritonitis in patients with peritoneal catheters.</p></div>
<div class="block mst drugH1Div" id="F147549"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cefotaxime may be confused with cefOXitin, cefuroxime</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Spectrocef [Italy] may be confused with Spectracef brand name for cefditoren [US, Great Britain, Mexico, Portugal, Spain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298990"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147465"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 grams per day with concurrent probenecid. Any patients receiving this combination should be monitored for evidence of cefotaxime toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F147482"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F5951413"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefotaxime crosses the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Cefotaxime is approved for use in women undergoing cesarean section (consult current guidelines for appropriate use).</p></div>
<div class="block mopp drugH1Div" id="F53565927"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis during first dose; monitor infusion site for extravasation; with prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea.</p></div>
<div class="block pha drugH1Div" id="F147459"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cefotaxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. <i>Enterococcus</i> species may be intrinsically resistant to cefotaxime. Most extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefotaxime. </p></div>
<div class="block phk drugH1Div" id="F147478"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to body tissues and fluids, including aqueous humor, ascitic and prostatic fluids, bone; penetrates cerebrospinal fluid (CSF) best when meninges are inflamed.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates (GA: 23 to 42 weeks; PNA: 0 to 69 days): Median: 0.64 L/kg (Leroux 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Median: 0.3 L/kg (range: 0.2 to 0.41 L/kg) (Béranger 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">CSF concentrations:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates (GA: 23 to 40 weeks; PNA: 3 to 88 days): Median: 28% (range: 6% to 76%) (Chen 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months and Children: 10.1% (range: 0% to 20%) (Trang 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 31% to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially hepatic to active metabolite, desacetylcefotaxime.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Cefotaxime: Prolonged with renal and/or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates: PNA &lt;7 days: 5.7 ± 0.8 hours; PNA 7 to 28 days: 3.5 ± 0.5 hours (Kafetzis 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates: PNA &lt;7 days: 3.4 ± 0.3 hours; PNA 7 to 28 days: 2 ± 0.4 hours (Kafetzis 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months, Children, and Adolescents ≤16 years: ~0.7 to 0.8 hours (Paap 1991; Trang 1985).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1 to 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Desacetylcefotaxime: Prolonged with renal impairment (Ings 1982; Paap 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥7 years and Adolescents ≤16 years: 2.04 ± 0.39 hours (Paap 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1.3 to 1.9 hours (Ings 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: Within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% as unchanged drug and metabolites).</p></div>
<div class="block phksp drugH1Div" id="F58536515"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent; associated with time free drug concentration (fT) &gt; minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (fT) &gt; MIC (bacteriostatic), ≥60% to 70% (fT) &gt; MIC (bactericidal) (Craig 1996; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients, C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">Steady state:</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥2 months of age and children: IV: 50 mg/kg/dose every 6 hours: ~142 mg/L (Kearns 1992).</p>
<p style="text-indent:-2em;margin-left:10em;">Single dose:</p>
<p style="text-indent:-2em;margin-left:12em;">Preterm and term neonates (GA: 27 to 40 weeks, PNA 0 to 3 days): IV: 50 mg/kg: ~120 to 200 mg/L (Baird-Lambert 1984).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥7 years of age and adolescents ≤16 years of age: 50 mg/kg (maximum dose: 2,000 mg) IV: ~175 to 180 mg/L (Paap 1991).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, C<sub>max</sub> (peak), single dose:</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg IM: 11.7 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg IV: 38.9 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:10em;">1 g IM: 20.5 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:10em;">1 g IV: 101.7 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:10em;">2 g IV: 214.4 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998; Hanberger 1991).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F147483"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ceftax | Claforan | Foxime | Primocef</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima | Cefotaxima fabra | Cefotaxima klonal | Cefotaxima norgreen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim abbott | Cefotaxim aptapharma | Cefotaxim eberth | Cefotaxim mip | Cefotaxim sandoz | Claforan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Dbl cefotaxime sod</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cefot | Ceftax | Cetaxim | Claforan | Maxcef | Taxceph | Taxim | Torped</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim sandoz | Cefotaxime Teva | Claforan</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Claforan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abricef | Cefotaxim | Cefotaxim mip | Cefotaxime avantx | Claforan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bactaxim | Ceforan | Cefotamax | Cefotaxima sodica | Cefoxima | Cetazima | Claforan | Clafordil | Kefaxim | Kefoxin | Kefozil | Losporin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Necaxime</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Grifotaxina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A fa lang | An de zhi | Cefajet | Cefomic | Cefotax | Cefotaxime | Celtex | Claforan | Claforan-huabei | Da li long | Di mo long | Er ye sai | Fu kang tai xin | Gao kang | Hai fu xun | Hai sai | Kai di long | Kai fu long | Ke man xin | Ke rui | Ke sai | La fa | Lei ke | Li jian shuai | Pu tai | Sai bi | Sai fu kang | Tai li sai | Xian kai | Xin li xin | Xing le | You sai | Zhi Jun Bi Tuo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima | Cefotaxime | Claforan | Deltafotan | Fotexina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefantral | Cefotaxim | Ceftax | Claforan | Sefotak | Taxcef | Taximed</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Cefotaxim Actavis | Cefotaxim eberth | Cefotaxim hexal | Cefotaxim saar | Cefotaxim stragen | Claforan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Benaxima | Cefot | Cefotax | Cefotaxima | Cefotaxima sintesis | Cefotaxina sodica | Claforan | Fotexina | Taxivil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima | Cefotaxime | Celaxin | Claforan | Fotexina | Grifotaxima</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Cefotaxime | Claforan | Valoran</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefause | Cefaxim | Ceforan | Cefotax | Cefotax t3a | Cefotaxime | Cefotaxime evapharma | Claforan | Foxime | Hebitaxime | Itotaxime | Pentatrox | Rametax | Sigmataxim | Sporitaxime | Taximodel | Vucefetex | Xorin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima bayvit | Cefotaxima Chiesi | Cefotaxima combino | Cefotaxima domac | Cefotaxima edigen | Cefotaxima Fresenius Kabi | Cefotaxima ges | Cefotaxima Ips | Cefotaxima Level | Cefotaxima Mayne | Cefotaxima normon | Cefotaxima rovi | Cefotaxima salvat | Cefotaxima torlan | Claforan | Valoran</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Cefotaxime atb | Necaxime | Theotax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim mip pharma | Cefotaxim sandoz | Claforan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime dakota | Cefotaxime Dci | Cefotaxime G Gam | Cefotaxime merck | Cefotaxime noridem | Cefotaxime panpharma | Cefotaxime Winthrop | Claforan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Cefotaxime sandoz | Claforan | Trav cefotaxime</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Claforan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ciltiren | Claforan | Letynol | Molelant | Phacocef | Spirosine | Stoparen | Vencyp</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Claforan | Pan Cefotaxime | Valoran</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cefalekol | Cefotaxim aptapharma | Cefotaxim mip | Claforan | Tirotax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Baxima | Biocef | Cefarin | Cefor | Cefotaxime | Cefovell | Cefoxal | Clacef | Claforan | Clatax | Combicef | Efotax | Ethiclaf | Foxim | Futacef | Glocef | Goforan | Hexitax | Incetax | Kalfoxim | Lancef | Lapixime | Primocef | Rycef | Soclaf | Starclaf | Taxecap | Taxef | Taxegram | Taxfor | Taximax | Tirdicef | Yaforan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Claforan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afitax | Alcef | Altax | Auract | Aurotax | Avicef | Axiom | Bestax | Biotax | Blutax | C tax | Cefantral | Cefatax | Cefatox | Cefaxil | Ceflin | Cefo | Cefomarc | Cefotax | Cefotaxim | Cefotaxime | Cefotim | Ceftal | Ceftex | Claforan | Desatax | Dexim | Efitax | Efotax | Epotax | Eratax | Evacef | Flamotax | Fotax | Gencef | Gramotax | Haltax | Ivitax | Lenocef | Lyforan | Medoaxim | Nepotax | Nilstat | Novatax | Nutaxin | Ominax | Omnatax | Omnicef | Oritaxim | Princef | Sifotaxim | Spinoceff | Stancef | Swiftax | Switax | Tax-o-bid | Taxicon | Taxim | Troycef | Widee | Zetaxim | Zoftax | Zovitax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aximad | Batixim | Cefomit | Cefotaxima | Cefotaxima ct | Cefotaxima eg | Cefotaxima jet | Cefotaxima sandoz | Cefotaxime | Cefotaxime acs | Cefotaxime merck generics | Cefotaxime piam | Cefotaxime prc | Centiax | Claforan | Lirgosin | Refotax | Salocef | Spectrocef | Tafocex | Taxime | Xame | Zariviz | Zimanel</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cefotax | Claforan | Naspor | Primocef | Sefotak | Taxime | Tirotax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cefotax aventis | Cefotax chugai | Claforan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cefotax | Evacef | Injtax | Inno tax | Maxcef | Nefatax | Nutaxin | Oritaxim | Sanfotax 1000 | Taxibiotic</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aju cefotaxime sodium | Algitaxime | Aprogen cefotaxime sodium | Asfotasim | Binex cefotaxime sodium | Cefaklon | Cefotac | Cefotam | Cefotaxime | Cefotaxime boryung | Cefotaxime sodium huons | Cefotaxime sodium yungjin | Cefoxim | Cepoxime | Cetaxime | CKD Cefotaxime | Claforan | Daewoong cefotaxime sodium | Dongkoo cefotaxime | Focetil | Gentaxime | Hanlim cefotaxime sodium | Hanmi cefotaxime sodium | Hantaxime | Hawon cefotaxime sodium | Huons Cefotaxime | Hwail cefotaxime sodium | Icure cefotaxime sodium | Il yang cefotaxime sodium | Infotaxime | Inno.n cefotaxime sodium | Jeil taxime | Joonghun cefotaxime | Joonghun cefotaxime sodium | K taxime | Korus cefotaxime sodium | Kukje cefotaxime | Kyongbo cefotaxime sodium | Medica cefotaxime | Neucellpita | Newtaxime | Pharma cefotaxime sodium | Samjin cefotaxime | Samjin cefotaxime sodium | Twowincefotaxime | Unitaxime | Wontaxime | Yooyoung cefotaxime sodium</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cefotax | Claforan | Foxime</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ceforan | Cefotax | Claforan | Claphorama</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abricef | Biotaksym | Cefotaxim | Cefotaxime | Cinkas | Claforan | Moxicef | Oritaxim | Spirosin | Tarcefoksym</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Claforan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Cefotaxime | Cefotaxime bcpp | Cefotaxime MIP | Cefotaxime sandoz | Cefotaximum Cipla | Claforan | Fotaxil | Novatax | Spirosin | Valoran</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cetaxon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alvim 1000 | Benaxima | Biosint | Cefotaxima | Cefotaxima gi merc | Cefotaxima gi pisa | Cefotaxima gi prec | Cefotaxima lem g.i | Cefotaxima Loeffler | Cefotex | Cefradil | Ceftomax | Claforan | Dolanex | Fot-amsa | Fotexina | Taporin | Taporin im | Taxisensi | Tebruxim | Tirotax | Viken | Xenlid im</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Claforan | Claraxim | Rekaxime</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Exef | Putaran | Razotax | Traforan | Uwanstaxime</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Cefotaxim abbott | Cefotaxim Eureco Pharma | Cefotaxim pch | Cefotaxime | Claforan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Cefotaxim navamedic | Cefotaxim sandoz | Cefotaxim stragen | Cefotaxime | Claforan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima | Ceftax | Claforan | Grifotaxima | Naspor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cefogram | Cefolan | Cefotax | Cefotaxime | Cetaxima | Cladex | Clafetam | Claforan | Clafoxim | Clinbaxef | Foximet | Haxim | Lac Xim | Pantaxin | Pharex cefotaxime | Sefotak | Sitixon | Taxim | Ximvex | Zefotax | Zentro</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adoxime | Alsef | Bacxime | Baxim | Bestsaf | Cafran | Cef so | Cefabest | Cefacron | Cefcam | Cefcan | Cefnixa | Cefocent | Cefogate | Cefomed | Cefomerc | Cefomic | Cefon | Ceforin | Cefotam | Cefotax | Cefotaxime | Cefoxim | Cefti | Ceftoringe | Cephronate | Cetax | Clacef | Clafort | Clavox | Cliver | Cynotax | Cyox | Daytaxime | Efatax | Elkotax | Evotaxime | Exef | Exoran | Fadtax | Faraxime | Fastimax | Fetaxime | Forax | Fotax | Foxime | Furitax | Fustexim | Futazim | Gen 3 | Getex | Gilaxim | Grecef | H-Cef | Hinxime | Hypertax | Incetax | Intek | Ixim | Jafotax | Jasper | Kalfoxin | Kanaxime | Macfran | Markxim | Mb-cef | Mediforan | Molelant | Nestox | Nitaxim | Oceclaf | Onexin | Orataxime | Palfotax | Pure Xim | Reftox | Samcef | Sefoban | Sefox | Sefoxime | Setex | Shintax | Sotaxim | Speedro | Spirosine | Sporonil | Suprax | Swiftax | Taxcef | Taxifer | Taxime | Taxiron | Taxium | Taxomic | Taxosa | Tefotaxime | Tokom | Toptaxim | Toximed | Tracer | Traxim | Treat | Valoran | Wintax | Wistax | Wontaxime | Xemeg | Xetaxime | Ximgal | Yorker | Zafixime | Zeref-s | Zintaxime</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biotaksym | Cefotaxim mip | Claforan | Rantaksym | Tarcefoksym | Tirotax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Claforan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Antadar | Cefobetox | Cefotaxima | Cefotaxima generis | Cefotaxima labesfal | Ralopar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima 1 g cefen guayaki | Cefotaxima ahimsa | Cefotaxima cipla | Cefotaxima dutriec | Cefotaxima farmed | Cefotaxima fasa pharma | Cefotaxima genfar | Cefotaxima klonal | Cefotaxima landerlan | Cefotaxima libra | Cefotaxima medical pharma | Cefotaxima millet | Cefotaxima prosalud | Cefotaxima variquin | Cefotaxima vitalis | Claforan | Grifotaxima | Justum | Primeris | Tizoxim</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ceforan | Cefotim | Cefotim IM | Ceftax | Cetax | Claforan | Claforan IM | Primocef | Primocef IM | Tirotax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim | Claforan | Spirosine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cefabol | Cefantral | Cefosin | Cefotaxim | Cefotaxim leksvm | Cefotaxim sandoz | Cefotaxime | Cefotaxime ds | Cefotaxime elfa | Cefotaxime lek | Cefotaxime vial | Cetax | Clafobrin | Claforan | Clafotaxim | Duatax | Intrataxim | Intrataxime | Liforan | Lyforan | Oritax | Oritaxim | Rezibelacta | Talcef | Tarcefoxim | Tax-o-bid | Tirotax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ceftax | Claforan | Clafotax | Foxime | Primocef</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxim copyfarm | Cefotaxim mip | Cefotaxim sandoz | Cefotaxim stragen | Cefotaxim teva | Claforan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Claforan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Cefotaksim | Cefotaksim actavis | Cefotaksim aptapharma | Cefotaxim stragen | Cefotaxima normon | Macrocef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abricef | Cefantral | Cefotaxim | Cefotaxim eberth | Claforan | Taxcef | Taximed | Tirotax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Biotax | Biotaxime | Cefomic | Ceforan | Cefotam | Cefotax | Cefotaxime | Cefox | Cefozan | Ceftaran | Ceftaxan | Claforan | Clafotax | Claraxim | Clatacef 3 | Fontax | Fotax | Motaxim | Necaxime | Valoran</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Cefotaxime panpharma | Cefotim | Claforan | Sefotak | Spirosine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Betaksim | Claforan | Deforan | Eqitax | Ieforan | Sefagen | Sefotak | Taksidem | Taxocef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime | Cefoxine | Cepor | Cetax | Cetaxima | Claforan | Clavox | Klaform | Loforan | Unitax</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cefabol | Cefantral | Cefotam | Cefotaxim | Cefotaxim Kmp | Cefotaxim mip | Cefotaxime | Claforan | Fagocef | Loraxim | Phacocef | Spirosin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ceforan | Evacef | Novatax | Oritaxim | Sefotax | Valoran</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxima | Cefotaxima winpharm | Cefotaxime | Cefotaxime Armstrong | Claforan | Primeris | Terasep | Ultracef</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefam | Cefatox | Cefot | Cefotas | Cefotaxima | Ceftax | Cextacim | Claforan | Oritaxim | Taxibon | Tirotax</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Artaxim | Braciti | Brutax | Cefolife | Cefovidi | Dolisepin | Fonxadin | Gold max | Goldcefo | Haboxime | Jincetaxime | Kbtaxime | Metacxim | Pasoxime | Taxibiotic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cefotaxime 0,5 g oethmaan | Cefotaxime fresenius | Kefotax | Klafotaxim | Oritaxim | Pharmacare cefotaxime | Reftax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Altax | Cefaxil | Cefo | Cefotax | Cefotaxime | Cetax | Clatax | Lyforan | Novatax | Oritaxim | Tax-o-bid | Taxim | Ucetaxime</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i> Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ryan.2020">
<a name="Ryan.2020"></a>Andrews J, John J, Charles RC. Enteric (typhoid and paratyphoid) fever: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20846891">
<a name="20846891"></a>Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. <i>Int J Infect Dis</i>. 2010;14(suppl 4):S79-S92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/20846891/pubmed" id="20846891" target="_blank">20846891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007, p 55, 149.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6330019">
<a name="6330019"></a>Baird-Lambert J, Doyle PE, Thomas D, Cvejic M, Buchanan N. Pharmacokinetics of cefotaxime in neonates. <i>J Antimicrob Chemother</i>. 1984;13(5):471-477. doi:10.1093/jac/13.5.471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/6330019/pubmed" id="6330019" target="_blank">6330019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2019">
<a name="Barshak.2019"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28980166">
<a name="28980166"></a>Béranger A, Oualha M, Urien S, et al. Population pharmacokinetic model to optimize cefotaxime dosing regimen in critically ill children. <i>Clin Pharmacokinet</i>. 2018;57(7):867-875. doi:10.1007/s40262-017-0602-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/28980166/pubmed" id="28980166" target="_blank">28980166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18791659">
<a name="18791659"></a>Bertels RA, Semmekrot BA, Gerrits GP, Mouton JW. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion. <i>Infection</i>. 2008;36(5):415-420. doi:10.1007/s15010-008-7274-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/18791659/pubmed" id="18791659" target="_blank">18791659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1893749">
<a name="1893749"></a>Bouchet JL, Aparicio M, Vinçon G, et al. Pharmacokinetic considerations for treatment of bacterial peritonitis during continuous ambulatory peritoneal dialysis. <i>Contrib Nephrol</i>. 1991;89:96-107. doi:10.1159/000419756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/1893749/pubmed" id="1893749" target="_blank">1893749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3494602">
<a name="3494602"></a>Bradley J, Francis J, Wheatley T. Liver abscess due to Haemophilus influenzae type b. <i>Eur J Clin Microbiol</i>. 1987;6(1):76-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/3494602/pubmed" id="3494602" target="_blank">3494602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9074846">
<a name="9074846"></a>Brogden RN, Spencer CM. Cefotaxime. A Reappraisal of Its Antibacterial Activity and Pharmacokinetic Properties, and a Review of Its Therapeutic Efficacy When Administered Twice Daily for the Treatment of Mild-to-Moderate Infections. <i>Drugs</i>. 1997;53(3):483-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/9074846/pubmed" id="9074846" target="_blank">9074846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25075836">
<a name="25075836"></a>Brouwer MC, Tunkel AR, McKhann GM 2nd, van de Beek D. Brain abscess. <i>N Engl J Med</i>. 2014;371(5):447-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/25075836/pubmed" id="25075836" target="_blank">25075836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefotaxime.1">
<a name="Cefotaxime.1"></a>Cefotaxime injection [prescribing information]. Eatontown, NJ: West-Ward; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefotaxime.2">
<a name="Cefotaxime.2"></a>Cefotaxime injection [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29437625">
<a name="29437625"></a>Chen XK, Shi HY, Leroux S, et al. Penetration of cefotaxime into cerebrospinal fluid in neonates and young infants. <i>Antimicrob Agents Chemother</i>. 2018;62(4):e02448-17. doi:10.1128/AAC.02448-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/29437625/pubmed" id="29437625" target="_blank">29437625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Claforan.1">
<a name="Claforan.1"></a>Claforan (cefotaxime) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis.</i> 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>CMNEEJ. </i>1991;13(16)121-128.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.<i> Pediatr Infect Dis J.</i> 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2393258">
<a name="2393258"></a>Deeter RG, Weinstein MP, Swanson KA, et al. Crossover Assessment of Serum Bactericidal Activity and Pharmacokinetics of Five Broad-Spectrum Cephalosporins in the Elderly. <i>Antimicrob Agents Chemother</i>. 1990;34(6):1007-1013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/2393258/pubmed" id="2393258" target="_blank">2393258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/wp-content/uploads/2023/01/GOLD-2023-ver-1.2-7Jan2023_WMV.pdf. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2019">
<a name="Goldenberg.2019"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522387">
<a name="17522387"></a>Halperin JJ, Shapiro ED, Logigian E, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2007;69(1):91-102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/17522387/pubmed" id="17522387" target="_blank">17522387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1794362">
<a name="1794362"></a>Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. <i>Eur J Clin Microbiol Infect Dis.</i> 1991;10(11):927-934. doi:10.1007/BF02005446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/1794362/pubmed" id="1794362" target="_blank">1794362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31432468">
<a name="31432468"></a>Hartman SJF, Brüggemann RJ, Orriëns L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature. <i>Clin Pharmacokinet</i>. 2020;59(2):173-205. doi:10.1007/s40262-019-00813-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/31432468/pubmed" id="31432468" target="_blank">31432468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35383374">
<a name="35383374"></a>Hartman SJF, Upadhyay PJ, Mathôt RAA, et al. Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. <i>J Antimicrob Chemother</i>. 2022;77(6):1725-1732. doi:10.1093/jac/dkac095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/35383374/pubmed" id="35383374" target="_blank">35383374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2020a">
<a name="Hohmann.2020a"></a>Hohmann El. Nontyphoidal salmonella: Gastrointestinal infection and carriage. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2020b">
<a name="Hohmann.2020b"></a>Hohmann El. Nontyphoidal salmonella bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 15, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6294787">
<a name="6294787"></a>Ings, RMJ, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. <i>Rev Infect Dis</i>. 1982;4(suppl): S379-S391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/6294787/pubmed" id="6294787" target="_blank">6294787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118‐126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6278118">
<a name="6278118"></a>Kafetzis DA, Brater DC, Kapiki AN, Papas CV, Dellagrammaticas H, Papadatos CJ. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. <i>J Pediatr</i>. 1982;100(3):483-489. doi:10.1016/s0022-3476(82)80466-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/6278118/pubmed" id="6278118" target="_blank">6278118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1606788">
<a name="1606788"></a>Kearns GL, Young RA, Jacobs RF. Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.<i> Clin Pharmacokinet</i>. 1992;22(4):284-297. doi:10.2165/00003088-199222040-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/1606788/pubmed" id="1606788" target="_blank">1606788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060760">
<a name="21060760"></a>Kim HS, Park DW, Youn YK, et al. Liver abscess and empyema due to Lactococcus lactis cremoris. <i>J Korean Med Sci</i>. 2010;25(11):1669-1671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/21060760/pubmed" id="21060760" target="_blank">21060760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klausner.2019">
<a name="Klausner.2019"></a>Klausner JD. Disseminated gonococcal infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7791418">
<a name="7791418"></a>Klein NC, Cunha BA. Third-Generation Cephalosporins. <i>Med Clin North Am</i>. 1995;79(4):705-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/7791418/pubmed" id="7791418" target="_blank">7791418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16239034">
<a name="16239034"></a>Kowlessar PI, O'Connell NH, Mitchell RD, Elliott S, Elliott TS. Management of patients with <i>Streptococcus milleri</i> brain abscesses. <i>J Infect</i>. 2006;52(6):443-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/16239034/pubmed" id="16239034" target="_blank">16239034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3415944">
<a name="3415944"></a>Lepage P, Bogaerts J, Kestelyn P, Meheus A. Single-dose cefotaxime intramuscularly cures gonococcal ophthalmia neonatorum. <i>Br J Ophthalmol</i>. 1988;72(7):518-520. doi:10.1136/bjo.72.7.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/3415944/pubmed" id="3415944" target="_blank">3415944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27572399">
<a name="27572399"></a>Leroux S, Roué JM, Gouyon JB, et al. A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants. <i>Antimicrob Agents Chemother</i>. 2016;60(11):6626-6634. doi:10.1128/AAC.01045-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/27572399/pubmed" id="27572399" target="_blank">27572399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3396489">
<a name="3396489"></a>Ludwig E, Székely É, Csiba A, et al. Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Elderly Patients. <i>Drugs</i>. 1988;35(suppl 2):51-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/3396489/pubmed" id="3396489" target="_blank">3396489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29378711">
<a name="29378711"></a>Maksoud E, Koehl B, Facchin A, et al. Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease. <i>Antimicrob Agents Chemother</i>. 2018;62(4):e00637-17. doi:10.1128/AAC.00637-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/29378711/pubmed" id="29378711" target="_blank">29378711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF, Blair JE. The Cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4006373">
<a name="4006373"></a>Matzke GR, Abraham PA, Halstenson CE, Keane WF. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. <i>Clin Pharmacol Ther</i>. 1985;38(1):31-36. doi:10.1038/clpt.1985.130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/4006373/pubmed" id="4006373" target="_blank">4006373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8235924">
<a name="8235924"></a>McCormack WM, Mogabgab WJ, Jones RB, Hook EW 3rd, Wendel GD Jr, Handsfield HH. Multicenter, comparative study of cefotaxime and ceftriaxone for treatment of uncomplicated gonorrhea. <i>Sex Transm Dis.</i> 1993;20(5):269-273. doi:10.1097/00007435-199309000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/8235924/pubmed" id="8235924" target="_blank">8235924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1952862">
<a name="1952862"></a>Paap CM, Nahata MC, Mentser MA, Mahan JD, Puri SK, Hubbard JW. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction. <i>Antimicrob Agents Chemother</i>. 1991;35(9):1879-1883. doi:10.1128/AAC.35.9.1879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/1952862/pubmed" id="1952862" target="_blank">1952862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2019">
<a name="Pemberton.2019"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.2">
<a name="manu.2"></a>Refer to Canadian manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA; American Association for the Study of Liver Diseases Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. https://www.aasld.org/sites/default/files/2019-06/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf. American Association for the Study of Liver Diseases. Published 2013. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2">
<a name="Runyon.2"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19168542">
<a name="19168542"></a>Seguin P, Verdier MC, Chanavaz C, et al. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. <i>J Antimicrob Chemother</i>. 2009;63(3):564-567. doi:10.1093/jac/dkn522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/19168542/pubmed" id="19168542" target="_blank">19168542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2021">
<a name="Sethi.2021"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164. doi:10.1086/649554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4083862">
<a name="4083862"></a>Trang JM, Jacobs RF, Kearns GL, et al. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. <i>Antimicrob Agents Chemother</i>. 1985;28(6):791-795. doi:10.1128/AAC.28.6.791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/4083862/pubmed" id="4083862" target="_blank">4083862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi: 10.1093/cid/ciw861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated September 28, 2022. Accessed November 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines</a>. Updated September 2, 2022. Accessed November 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DHSS.2020">
<a name="DHSS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16869814">
<a name="16869814"></a>van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. <i>Br J Clin Pharmacol</i>. 2007;63(1):100-109. doi:10.1111/j.1365-2125.2006.02730.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/16869814/pubmed" id="16869814" target="_blank">16869814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.2021">
<a name="Vollmer.2021"></a>Vollmer CM. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int</i>. 2012;(32)(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4055047">
<a name="4055047"></a>Wise R, Wright N. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. <i>Infection</i>. 1985;13(suppl 1):S145-S150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/4055047/pubmed" id="4055047" target="_blank">4055047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA; Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep. </i>2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotaxime-united-states-limited-availability-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2003">
<a name="WHO.2003"></a>World Health Organization (WHO). Background document: The diagnosis, treatment and prevention of typhoid fever. https://www.glowm.com/pdf/WHO-diagnosis%20treatment%20prevention%20of%20typhoid%20fever-2003-CustomLicense.pdf. Published 2003.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 13129 Version 289.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
